vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与TRICO BANCSHARES （TCBK）财务数据对比。点击上方公司名可切换其他公司
TRICO BANCSHARES 的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.4倍（$109.4M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 9.0%），TRICO BANCSHARES 自由现金流更多（$127.9M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 5.4%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Trico Bancshares是一家总部位于美国的区域银行控股公司，旗下运营Tri Counties Bank，主要为北加利福尼亚州的个人消费者和中小企业提供存款、房贷、小微企业融资、财富管理等各类零售及商业银行服务。
PBYI vs TCBK — 直观对比
营收规模更大
TCBK
是对方的1.4倍
$75.5M
营收增速更快
PBYI
高出18.7%
9.0%
自由现金流更多
TCBK
多$113.5M
$14.4M
两年增速更快
PBYI
近两年复合增速
5.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $109.4M |
| 净利润 | — | $33.6M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 42.6% |
| 净利率 | — | 251.6% |
| 营收同比 | 27.7% | 9.0% |
| 净利润同比 | — | 15.8% |
| 每股收益（稀释后） | $0.26 | $1.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYITCBK
| Q4 25 | $75.5M | $109.4M | ||
| Q3 25 | $54.5M | $107.6M | ||
| Q2 25 | $52.4M | $103.6M | ||
| Q1 25 | $46.0M | $98.6M | ||
| Q4 24 | $59.1M | $100.4M | ||
| Q3 24 | $80.5M | $99.1M | ||
| Q2 24 | $47.1M | $97.9M | ||
| Q1 24 | $43.8M | $98.5M |
净利润PBYITCBK
| Q4 25 | — | $33.6M | ||
| Q3 25 | $8.8M | $34.0M | ||
| Q2 25 | $5.9M | $27.5M | ||
| Q1 25 | $3.0M | $26.4M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $20.3M | $29.1M | ||
| Q2 24 | $-4.5M | $29.0M | ||
| Q1 24 | $-4.8M | $27.7M |
毛利率PBYITCBK
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYITCBK
| Q4 25 | 22.7% | 42.6% | ||
| Q3 25 | 17.6% | 43.2% | ||
| Q2 25 | 12.7% | 36.5% | ||
| Q1 25 | 8.7% | 35.8% | ||
| Q4 24 | 22.6% | 38.7% | ||
| Q3 24 | 27.4% | 39.8% | ||
| Q2 24 | -4.6% | 40.0% | ||
| Q1 24 | -5.3% | 38.3% |
净利率PBYITCBK
| Q4 25 | — | 251.6% | ||
| Q3 25 | 16.2% | 31.6% | ||
| Q2 25 | 11.2% | 26.6% | ||
| Q1 25 | 6.5% | 26.7% | ||
| Q4 24 | — | 221.4% | ||
| Q3 24 | 25.2% | 29.3% | ||
| Q2 24 | -9.6% | 29.7% | ||
| Q1 24 | -11.0% | 28.2% |
每股收益（稀释后）PBYITCBK
| Q4 25 | $0.26 | $1.02 | ||
| Q3 25 | $0.17 | $1.04 | ||
| Q2 25 | $0.12 | $0.84 | ||
| Q1 25 | $0.06 | $0.80 | ||
| Q4 24 | $0.40 | $0.88 | ||
| Q3 24 | $0.41 | $0.88 | ||
| Q2 24 | $-0.09 | $0.87 | ||
| Q1 24 | $-0.10 | $0.83 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $157.0M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $1.3B |
| 总资产 | $216.3M | $9.8B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYITCBK
| Q4 25 | $97.5M | $157.0M | ||
| Q3 25 | $94.4M | $298.8M | ||
| Q2 25 | $96.0M | $314.3M | ||
| Q1 25 | $93.2M | $308.3M | ||
| Q4 24 | $101.0M | $145.0M | ||
| Q3 24 | $96.7M | $320.1M | ||
| Q2 24 | $96.8M | $206.6M | ||
| Q1 24 | $107.2M | $82.8M |
总债务PBYITCBK
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYITCBK
| Q4 25 | $130.3M | $1.3B | ||
| Q3 25 | $115.3M | $1.3B | ||
| Q2 25 | $104.7M | $1.3B | ||
| Q1 25 | $97.1M | $1.3B | ||
| Q4 24 | $92.1M | $1.2B | ||
| Q3 24 | $71.1M | $1.2B | ||
| Q2 24 | $48.5M | $1.2B | ||
| Q1 24 | $51.0M | $1.2B |
总资产PBYITCBK
| Q4 25 | $216.3M | $9.8B | ||
| Q3 25 | $202.9M | $9.9B | ||
| Q2 25 | $194.9M | $9.9B | ||
| Q1 25 | $196.2M | $9.8B | ||
| Q4 24 | $213.3M | $9.7B | ||
| Q3 24 | $220.7M | $9.8B | ||
| Q2 24 | $205.0M | $9.7B | ||
| Q1 24 | $214.1M | $9.8B |
负债/权益比PBYITCBK
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $133.3M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $127.9M |
| 自由现金流率自由现金流/营收 | 19.1% | 116.9% |
| 资本支出强度资本支出/营收 | 0.0% | 4.9% |
| 现金转化率经营现金流/净利润 | — | 3.96× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $222.2M |
8季度趋势，按日历期对齐
经营现金流PBYITCBK
| Q4 25 | $14.4M | $133.3M | ||
| Q3 25 | $9.7M | $45.1M | ||
| Q2 25 | $14.1M | $29.2M | ||
| Q1 25 | $3.6M | $24.5M | ||
| Q4 24 | $15.6M | $109.7M | ||
| Q3 24 | $11.0M | $28.6M | ||
| Q2 24 | $1.0M | $31.8M | ||
| Q1 24 | $11.2M | $25.1M |
自由现金流PBYITCBK
| Q4 25 | $14.4M | $127.9M | ||
| Q3 25 | $9.7M | $43.2M | ||
| Q2 25 | $14.1M | $28.2M | ||
| Q1 25 | $3.6M | $22.8M | ||
| Q4 24 | $15.6M | $105.2M | ||
| Q3 24 | $11.0M | $27.3M | ||
| Q2 24 | $1.0M | $30.8M | ||
| Q1 24 | — | $24.1M |
自由现金流率PBYITCBK
| Q4 25 | 19.1% | 116.9% | ||
| Q3 25 | 17.7% | 40.2% | ||
| Q2 25 | 26.8% | 27.2% | ||
| Q1 25 | 7.7% | 23.1% | ||
| Q4 24 | 26.4% | 104.8% | ||
| Q3 24 | 13.7% | 27.6% | ||
| Q2 24 | 2.1% | 31.5% | ||
| Q1 24 | — | 24.4% |
资本支出强度PBYITCBK
| Q4 25 | 0.0% | 4.9% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.1% | 1.7% | ||
| Q4 24 | 0.0% | 4.5% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 1.0% | ||
| Q1 24 | 0.0% | 1.0% |
现金转化率PBYITCBK
| Q4 25 | — | 3.96× | ||
| Q3 25 | 1.10× | 1.33× | ||
| Q2 25 | 2.41× | 1.06× | ||
| Q1 25 | 1.21× | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | 0.54× | 0.98× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 0.90× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
